and Fcfusionproteinsfortherapeutic use MONOCLONAL ANTIBODIES Familial hypercholesterolemia Severe eosinophilicasthma HAEMOSTASIS AND THROMBOSIS Percutaneous coronary Head andneckcancer Reversal ofDabigatran Fallopian tubecancer Atypical hemolytic Cryopyrinopathies Colorectal cancer Malignant ascites uremic syndrome Bone metastasis Unstable angina Cervical cancer Allergic asthma Ovarian cancer Neuroblastoma GENETIC DISEASES Gastric cancer Kidney cancer Haemophilia A Haemophilia B Breast cancer Lung cancer SOLID TUMORS intervention PNEUMOLOGY CARDIOLOGY Melanoma DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION denosumab catumaxomab dinutuximab pembrolizumab nivolumab ipilimumab nivolumab bevacizumab bevacizumab bevacizumab bevacizumab cetuximab ramucirumab trastuzumab trastuzumab entansine pertuzumab bevacizumab trastuzumab aflibercept panitumumab cetuximab bevacizumab necitumumab nivolumab bevacizumab idarucizumab eftrenonacog α efmoroctocog α abciximab eculizumab canakinumab alirocumab evolocumab mepolizumab omalizumab Chronic lymphocyticleukaemia Chronic spontaneousurticaria Acute lymphocyticleukaemia Idiopathic thrombocytopenic Non-hodgkin’s lymphoma Acute myeloid leukaemia Paroxysmal nocturnal Castleman’s disease Hodgkin’s lymphoma Age relatedmacular HAEMATOLOGIC DISEASES neovascularization Multiple myeloma Myopic choroidal GASTROENTEROLOGY haemoglobinuria Ulcerative colitis Crohn’s disease Macular edema OPHTALMOLOGY degeneration DERMATOLOGY Psoriasis purpura omalizumab secukinumab ustekinumab adalimumab infliximab etanercept vedolizumab adalimumab infliximab vedolizumab golimumab adalimumab infliximab eculizumab romiplostim elotuzumab daratumumab siltuximab gemtuzumab ozogamicine inotuzumab ozogamicine blinatumomab obinutuzumab ofatumumab alemtuzumab rituximab brentuximab vedotin inotuzumab ozogamicine brentuximab vedotin ibritumomab tiuxetan rituximab aflibercept ranibizumab ranibizumab aflibercept ranibizumab bevacizumab aflibercept
Systemic lupuserythematosus Graft versus hostdisease Prevention ofrespiratory syncytial virusinfection Ankylosing spondylitis Rheumatoid arthritis Transplant rejection Multiple sclerosis INFECTIOUS DISEASES Anthrax infection Psoriatic arthritis Juvenile arthritis TRANSPLANTATION Gouty arthritis Osteoporosis RHUMATOLOGY IMMUNOLOGY NEUROLOGY canakinumab canakinumab tocilizumab abatacept adalimumab etanercept secukinumab certolizumab pegol golimumab adalimumab etanercept infliximab secukinumab certolizumab pegol ustekinumab golimumab infliximab adalimumab etanercept golimumab certolizumab pegol tocilizumab abatacept rituximab adalimumab infliximab etanercept denosumab inolimomab belatacept basiliximab raxibacumab palivizumab daclizumab alemtuzumab natalizumab belimumab
02/2016 Université François-Rabelais - SID’com - Alexandra Louault